Microsoft vs Nuvalent Inc — how do they compare? Microsoft trades at $396.8 (market cap $2.99T), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Microsoft is far larger — about 304.8× Nuvalent Inc's market cap, and Microsoft pays a 0.9% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MSFT | NUVL | |
|---|---|---|
Market Cap | $2.99T | $9.81B |
Volume | 36,654,621 | — |
Sector | Technology | Technology |
52-Week High | $542.07 | $123.96 |
52-Week Low | $352.83 | $72.16 |
Enterprise Value | $2.97T | $8.52B |
Dividend Yield | 0.9% | — |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.
The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →